Publications by Professor Helen Reeves - ePrints

Browsing publications by Professor Helen Reeves.

Newcastle Authors	Title	Year
Professor Helen Reeves Dr Dina Tiniakos	British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults	2024
Professor Helen Reeves	Impact of clonal hematopoiesis of indeterminate potential on hepatocellular carcinoma in individuals with steatotic liver disease	2024
Dr Kate Hallsworth Misti McCain Dr Morven Brown Dr Sam Orange Professor Helen Reeves et al.	Is home-based, virtually-delivered, group exercise feasible and acceptable for older patients with hepatocellular carcinoma? A non-randomised feasibility study (TELEX-Liver Cancer)	2024
Dr Steven Masson Professor Helen Reeves	Neddylation inhibition prevents acetaminophen-induced liver damage by enhancing the anabolic cardiolipin pathway	2024
Dr Jack Leslie Dr Jill Hunter Amy Collins Amelia Rushton Lauren Russell et al.	c-Rel–dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesis	2023
Professor Helen Reeves Misti McCain	Discriminatory Changes in Circulating Metabolites as a Predictor of Hepatocellular Cancer in Patients with Metabolic (Dysfunction) Associated Fatty Liver Disease	2023
Dr Kate Hallsworth Dr Sam Orange Misti McCain Professor Helen Reeves	Feasibility of a home-based, virtually-delivered, group exercise intervention in older patients with liver cancer (TELEX-Liver Cancer)	2023
Chalermsin Permtermsin - Lalchungnunga Dr Sirintra Nakjang John Casement Dr Laura Ogle et al.	Identification of TIAM1 as a Potential Synthetic-Lethal-like Gene in a Defined Subset of Hepatocellular Carcinoma	2023
Bassier Zadran Daniel Wainwright Dr Yvonne Bury Dr Saimir Luli Rachel Howarth et al.	Impact of retrotransposon protein L1 ORF1p expression on oncogenic pathways in hepatocellular carcinoma: the role of cytoplasmic PIN1 upregulation	2023
Dr Brian Ford Dr Shruti Chachra Katrina Rodgers Tabassum Moonira Dr Ziad Al-Oanzi et al.	The GCKR-P446L gene variant predisposes to raised blood cholesterol and lower blood glucose in the P446L mouse-a model for GCKR rs1260326	2023
Professor Helen Reeves John Hammond	The hepatocellular carcinoma Early Recurrence Score (ERS)—Ready for clinical implementation?	2023
Dr Daniel Geh Robyn Watson Gourab Sen Jeremy French John Hammond et al.	COVID-19 and liver cancer: Lost patients and larger tumours	2022
Dr Jack Leslie Erik Ramon Gil Kathryn Gilroy Dr Saimir Luli Maja Laszczewska et al.	CXCR2 inhibition enables NASH-HCC immunotherapy	2022
Professor Helen Reeves Dr Steven Masson	Genetic and pharmacological inhibition of XBP1 protects against APAP hepatotoxicity through the activation of autophagy	2022
Dr Daniel Geh Dr Jack Leslie Professor Helen Reeves Professor Derek Mann	Neutrophils as potential therapeutic targets in hepatocellular carcinoma	2022
Professor Helen Reeves Robyn Watson	Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study	2022
Dr Luca Miele Professor Helen Reeves	Rare ATG7 genetic variants predispose patients to severe fatty liver disease	2022
Dr Steven Masson Misti McCain Professor Helen Reeves	Restoring cellular magnesium balance through Cyclin M4 protects against acetaminophen-induced liver damage	2022
Professor Helen Reeves Professor Derek Manas Dr Peter Littler	Selective internal radiation therapy (SIRT) for hepatocellular carcinoma (HCC): Informing clinical practice for multidisciplinary teams in England	2022
Dr Marco Zaki Dr Sari Alhasan Dr Ruchi Shukla Misti McCain Maja Laszczewska et al.	Sulfatase-2 from Cancer Associated Fibroblasts: An Environmental Target for Hepatocellular Carcinoma?	2022
Dr Sam Orange Dr Kate Hallsworth Dr Morven Brown Professor Helen Reeves	The feasibility and acceptability of a home-based, virtual exercise intervention for older patients with hepatocellular carcinoma: protocol for a non-randomised feasibility study (TELEX-Liver Cancer)	2022
Nardeen Eldafashi Dr Rebecca Darlay Dr Ruchi Shukla Misti McCain Robyn Watson et al.	A pdcd1 role in the genetic predisposition to nafld-hcc?	2021
Misti McCain Professor Helen Reeves	Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity	2021
Professor Helen Reeves	Assessing the impact of COVID-19 on liver cancer management (CERO-19)	2021
Misti McCain Professor Derek Mann Professor Helen Reeves	Cell-free DNA TAPS provides multimodal information for early cancer detection	2021
Professor Helen Reeves Professor Arun Sanyal	Corrigendum to ‘Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis’ [J Hepatol 75 (2021) 865–878]	2021
Dr Praveen Dhondurao Sudhindar Daniel Wainwright Dr Santu Saha Rachel Howarth Misti McCain et al.	HCV Activates Somatic L1 Retrotransposition—A Potential Hepatocarcinogenesis Pathway	2021
Marco Zaki Dr Ahmed Mahdi Dr Gillian Patman Anna Whitehead Joao Mauricio et al.	Key features of the environment promoting liver cancer in the absence of cirrhosis	2021
Dr Catherine Willoughby Professor Helen Reeves Professor Arun Sanyal	Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis	2021
Dr Jack Leslie Dr Marie-Helene Ruchaud Amy Collins Leena Habiballa Dr Gabi Saretzki et al.	Neutrophils induce paracrine telomere dysfunction and senescence in ROS-dependent manner	2021
Dr Luca Miele Professor Quentin Anstee Professor Helen Reeves	Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores	2021
Professor Helen Reeves Professor Derek Manas Steven White	Treatment strategies for early stage hepatocellular carcinoma: a systematic review and network meta-analysis of randomised clinical trials	2021
Professor Helen Reeves	Characterisation of the Serum Metabolic Signature of Cholangiocarcinoma in a United Kingdom Cohort	2020
Dr Ruchi Shukla Professor Helen Reeves Professor Stuart McPherson Misti McCain Dr Praveen Dhondurao Sudhindar et al.	Hepatitis C virus infection, endogenous retrotransposons activation and cancer risk	2020
Sebastian Mafeld Professor Helen Reeves Professor Derek Manas Dr Peter Littler	Early Experience of Trans-arterial Chemo-Embolisation for Hepatocellular Carcinoma with a Novel Radiopaque Bead	2019
Professor Quentin Anstee Professor Helen Reeves Dr Olivier Govaere	From NASH to HCC: current concepts and future challenges	2019
Misti McCain Dr Luca Miele Professor Helen Reeves	Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease	2019
Dr Catherine Willoughby Huw Thomas Dr Elaine Willmore Suzanne Kyle Dr Anita Wittner et al.	Selective DNA-PKcs Inhibition Extends the Therapeutic Index of Localized Radiotherapy and Chemotherapy	2019
Professor Alastair Burt Professor Pierre Bedossa Professor Helen Reeves	Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR)	2018
Dr Dina Tiniakos Joao Pais Maurício-Muir Professor Helen Reeves	Fatty liver disease and hepatocellular carcinoma: The pathologist’s view	2018
Professor Jelena Mann Professor Helen Reeves	Liquid biopsy for liver diseases	2018
Dr Jane Margetts Laura Ogle Dr Anthony Chan Dr David Jamieson Dr Catherine Willoughby et al.	Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?	2018
Dr Richard McNally Professor Helen Reeves	Reply to ‘Comment on ‘Circulating Neutrophils in patients with hepatocellular carcinoma”	2018
Misti McCain Professor Helen Reeves	The biomarker potential of Ki67 and pH2AX immunohistochemistry in guiding use of the liver-targeting nucleotide MIV-818 in patients with hepatocellular carcinoma	2018
Professor Derek Manas Professor Helen Reeves	Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease	2017
Misti McCain Dr Luca Miele Dr Paula Iruzubieta Professor Helen Reeves Professor Quentin Anstee et al.	MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals	2017
Dr Ziad Al-Oanzi Sofia Fountana Tabassum Moonira Dr Susan Tudhope John Petrie et al.	Opposite effects of a glucokinase activator and metformin on glucose-regulated gene expression in hepatocytes	2017
Dr Lucy Walker Professor Ann Daly Dr Luca Miele Professor Quentin Anstee Professor Helen Reeves et al.	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease	2017
Dr Paula Iruzubieta Dr Steven Masson Misti McCain Professor Helen Reeves	The mitochondrial negative regulator MCJ is a therapeutic target for acetaminophen-induced liver injury	2017
Professor Helen Reeves	Assessment of the Hong Kong Liver Cancer Staging System in Europe	2016
Dr Catherine Willoughby Professor Helen Reeves	Combination PARP and HDAC inhibition as a therapeutic strategy targeting liver cancer stem cells?	2016
Tristan Reuillon Dr Sari Alhasan Dr Gary Beale Annalisa Bertoli Alfie Brennan et al.	Design and synthesis of biphenyl and biphenyl ether inhibitors of sulfatases	2016
Professor Helen Reeves	EASL Clinical Practice Guidelines on the management of benign liver tumours	2016
Professor Helen Reeves Marco Zaki Professor Chris Day	Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD	2016
Barry Dent Laura Ogle Dr Rachel O'Donnell Dr Ujjal Mallick Professor Nicola Curtin et al.	High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers	2016
Laura Ogle Dr James Orr Dr Catherine Willoughby Dr Claire Hutton Professor Stuart McPherson et al.	Imagestream detection and characterisation of circulating tumour cells - a liquid biopsy for hepatocellular carcinoma?	2016
Dr Mat Elameer Jeremy French Professor Derek Manas Professor Helen Reeves Dr Peter Littler et al.	Implementation of a one-stop multidisciplinary clinic for liver-directed therapy in patients with primary or secondary liver malignancies	2016
Professor Helen Reeves Professor Derek Manas	Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade	2016
Professor Helen Reeves	Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients	2016
Dr Sari Alhasan Dr Beate Haugk Laura Ogle Dr Gary Beale Anna Long et al.	Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinoma	2016
Marco Zaki Professor Helen Reeves	The genetic heterogeneity of hepatocellular carcinoma and the implications for personalised medicine	2016
Dr Sheba Macheka Dr David Jamieson Professor Helen Reeves Misti McCain	The isolation and characterisation of circulating tumour cells from patients with hepatocellular carcinoma	2016
Professor Helen Reeves	Urinary Metabotyping of Hepatocellular Carcinoma in a UK Cohort Using Proton Nuclear Magnetic Resonance Spectroscopy	2016
Dr Richard Speight Anna Whitehead Dr Gillian Patman Dr John Mansfield Professor Helen Reeves et al.	Activation of the bile acid receptor, Farnesoid-X Receptor, may reduce Ileal Inflammatory Cytokine expression in an animal model of diet-induced obesity	2015
Professor Helen Reeves	Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach - The ALBI Grade	2015
Professor Helen Reeves	Assessment of the Hong Kong Liver Cancer Staging System in Europe	2015
Liam Cornell Dr Joanne Martin Laura Ogle Dr Catherine Willoughby Dr Despina Televantou et al.	DNA-PK-A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival	2015
Anna Whitehead Dr Gillian Patman Professor Chris Day Dr Dina Tiniakos Professor Quentin Anstee et al.	Effects of FXR agonist PX20606 on tumour formation in animal models of non-alcoholic fatty liver disease	2015
Professor Helen Reeves	Hepatocellular Carcinoma: Optimal Staging Impacts Survival	2015
Anna Whitehead Laura Ogle Dr Gillian Patman Dr Ali Anwar Dr Dina Tiniakos et al.	Ras and p-ERK in metabolic syndrome associated Hepatocellular Carcinoma (HCC)	2015
Duncan Miller Dr Benoit Carbain Dr Gary Beale Dr Sari Alhasan Professor Helen Reeves et al.	Regioselective sulfamoylation at low temperature enables concise syntheses of putative small molecule inhibitors of sulfatases	2015
Dr Cedric Simillion Professor Helen Reeves	Regular exercise decreases liver tumors development in hepatocyte-specific PTEN-deficient mice independently of steatosis	2015
Professor Quentin Anstee Dr Yang-Lin Liu Professor Chris Day Professor Helen Reeves	Reply to: HCC and liver disease risk in homozygous PNPLA3 p.I148M carriers approach monogenic inheritance	2015
Professor Helen Reeves Dr Luca Miele Professor Quentin Anstee	Telomerase reverse transcriptase mutations are associated with hepatocellular carcinoma in nash	2015
Professor Helen Reeves	The 'Galad Score' for serological Detection of Hepatocellular Cercinoma: International Validation and Assesment of the Influence of Tumor size and Aetiology on Model Utility	2015
Professor Helen Reeves	A positive feedback loop between RIP3 and JNK controls non-alcoholic steatohepatitis	2014
Dr Yang-Lin Liu Dr Gillian Patman Julian Leathart Professor Alastair Burt Professor Chris Day et al.	Carriage of the PNPLA3 rs738409 C>G Polymorphism Confers an Increased Risk of Non-Alcoholic Fatty Liver Disease Associated Hepatocellular Carcinoma	2014
Barry Dent Dr Rachel O'Donnell Laura Ogle Padmini Ramesh Nick Hayes et al.	Detection and characterization of circulating tumor cells by imaging flow cytometry	2014
Dr Laura Ogle Dr David Jamieson Dr Rachel O'Donnell Barry Dent Professor Nicola Curtin et al.	Detection of circulating tumour cells (CTCS) in hepatocellular (HCC) cancer patients using the ImageStream^x	2014
Dr Jess Dyson Dr Dipanker Chattopadhyay Rajiv Lochan Jayadeva Dr Imran Patanwala Mike Cole et al.	Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team	2014
Professor Quentin Anstee Dr Mark Hudson Professor Helen Reeves	Reply to "Hepatocellular carcinoma and the Newcastle-upon-Tyne area"	2014
Dr Gillian Patman Professor Helen Reeves	The Detection of Hepatocellular Carcinoma Using a Prospectively Developed and Validated Model Based on Serological Biomarkers	2014
Dr Yang-Lin Liu Professor Helen Reeves Professor Alastair Burt Dr Dina Tiniakos Professor Stuart McPherson et al.	TM6SF2 rs58542926 Influences Hepatic Fibrosis Progression in Patients with Non-Alcoholic Fatty Liver Disease	2014
Anna Whitehead Dr Gillian Patman Liam Cornell Dr Despina Televantou Professor Nicola Curtin et al.	A Role for DNA Repair Protein Kinase (DNA-PK) in the Progression of Simple Steatosis to Steatohepatitis (NASH)?	2013
Dr Yang-Lin LIU Dr Gillian Patman Julian Leathart Professor Alastair Burt Professor Chris Day et al.	Carriage of PNPLA3 I148M is Associated with an Increased Risk of Non-Alcoholic Fatty Liver Disease Associated Hepatocellular Carcinoma	2013
Professor Helen Reeves	Effect of Regular Training on Hepatocellular Carcinoma Development in Hepatocyte-Specific Pten-Deficient Mice	2013
Professor Chris Day Professor Mark Walker Professor Helen Reeves	Krüppel Like Factor 6 (KLF6) Protects From NAFLD Progression through Regulation of Adipose Tissue Insulin Resistance	2013
Dr Gillian Patman Dr Despina Televantou Anna Whitehead Professor Chris Day Professor Fiona Oakley et al.	Mild Steatosis and Impaired Glucose Tolerance are Associated with Liver Cancer Development, While Progression to Nash Increases Number/Size in an Animal Model of NAFLD	2013
Dr Gillian Patman Professor Loranne Agius Douglas Hui Dr Despoina Televantou Professor Helen Reeves et al.	Post-transcriptional activation of PPAR alpha by KLF6 in hepatic steatosis	2013
Dr Gillian Patman Dr Despina Televantou Anna Whitehead Professor Chris Day Professor Alastair Burt et al.	Sulfatase-2 (SULF2) Expressed in Hepatocytes and Stromal Cells Contributes to the Development of Steatosis, the Progression of NAFLD to Fibrosis and the Advancement of Cancer	2013
John Petrie Dr Gillian Patman Ishita Sinha Professor Helen Reeves Professor Loranne Agius et al.	The rate of production of uric acid by hepatocytes is a sensitive index of compromised cell ATP homeostasis	2013
Liam Cornell Dr Joanne Martin Professor Nicola Curtin Professor Helen Reeves	DNA-PK or ATM inhibition inhibits non-homologous end joining and enhances chemo- and radio sensitivity in hepatocellular cancer cell lines	2012
Professor Quentin Anstee Dr Rebecca Darlay Julian Leathart Professor Helen Reeves Professor Alastair Burt et al.	Genome-Wide Association Analysis Confirms Importance of PNPLA3 and Identifies Novel Variants Associated With Histologically Progressive Steatohepatitis in NAFLD	2012
Dr Gillian Patman Laura Pascoe Dr Luca Miele Douglas Hui Professor Alastair Burt et al.	Glucokinase links Krüppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease	2012
Douglas Hui Stuart Robinson Dr Gillian Patman Professor Derek Manas Professor Helen Reeves et al.	KLF6 splice variant 1 in patients with colorectal liver metastasis correlates with a higher clinical risk score	2012
Dr Gillian Patman Douglas Hui Professor Quentin Anstee Professor Helen Reeves	Kruppel-like factor 6 splice variant 3 (KLF6-SV3) - The redox sensitive splice variant of KLF6 expressed in non-alcoholic steatohepatitis (NASH)	2012
Dr Despoina Televantou Douglas Hui Rajiv Lochan Jayadeva Richard Charnley Professor Alastair Burt et al.	Membranous expression of sulfatase-2 is associated with a poorer prognosis in patients following pancreatic cancer resection	2012
Dr Gillian Patman Douglas Hui Professor Quentin Anstee Professor Helen Reeves	Oxidative stress induces alternative splicing and nuclear translocation of kruppel like factor 6	2012
Dr Sari Alhasan Dr Gary Beale Professor Herbie Newell Professor Helen Reeves	Suppression of SULF2, an extracellular endosulfatase up-regulated in hepatocellular cancers, modulates WNT signalling and inhibits cell growth	2012
Professor Helen Reeves Professor Loranne Agius	The Kruppel-like factor 6-IVS1-27A (KLF6) polymorphism is associated with more favourable postprandial glucose metabolism in subjects at high risk of type 2 diabetes	2012
Rajiv Lochan Jayadeva Professor Ann Daly Professor Helen Reeves Richard Charnley	Family history of cancer and tobacco exposure in index cases of pancreatic ductal adenocarcinoma	2011
Dr Gillian Patman Professor Quentin Anstee Professor Helen Reeves	Hepatocellular Carcinoma in NASH: Is there a biological Rationale?	2011
Dr Imran Patanwala Professor Derek Manas Dr Mark Hudson Professor Helen Reeves	NAFLD and the changing face of hepatocellular cancerER (HCC)	2011
Dr Imran Patanwala Dr John Rose Bryon Jaques Professor Derek Manas Dr Mark Hudson et al.	NAFLD related HCC is rising dramatically in the North of England	2011
Rajiv Lochan Jayadeva Professor Ann Daly Professor Helen Reeves Richard Charnley	The role of tobacco derived carcinogens in pancreas cancer	2011
Laura Pascoe Dr Luca Miele Professor Helen Reeves	Kruppel like factor 6 (KLF6) regulates heaptic insulin resistance (HEP-IR)	2010
Dr Gillian Patman Professor Loranne Agius Professor Helen Reeves	Liver-specific deletion of KLF6 uncovers novel transcriptional pathways linked to lipid and glucose homeostasis	2010
Liam Cornell Dr Joanne Martin Febrina Budhisetiawan Professor Herbie Newell Professor Derek Manas et al.	Synthetic lethality in liver cancer cell lines treated with inhibitors of DNA double strand break repair	2010
Dr Joseph Gray Dr Dipanker Chattopadhyay Dr Gary Beale Dr Gillian Patman Dr Luca Miele et al.	A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease	2009
Dr Gary Beale Ahmad Alserri Dr Luca Miele Dr Gillian Patman Professor Ann Daly et al.	Claudin 10 (CLDN10) - a Candidate Suceptibility Gene for NAFLD Progression	2009
Dr Gillian Patman Professor Helen Reeves	Kruppel-like factor 6 in chronic liver disease and hepatocellular cancer	2009
Dr Gary Beale Laura Pascoe Dr Luca Miele Professor Mark Walker Professor Chris Day et al.	The Kruppel-Like Factor 6 (KLF6) Genotype Which is Associated With NAFLD Progression is Associated with Higher Fasting Serum Glucose Levels in Healthy Individuals	2009
Dr Gary Beale Dr Dipanker Chattopadhyay Dr Joseph Gray Dr Stephen Stewart Dr Mark Hudson et al.	AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease	2008
Rajiv Lochan Jayadeva Professor Ann Daly Professor Helen Reeves Richard Charnley	Genetic susceptibility in pancreatic ductal adenocarcinoma	2008
Dr Luca Miele Dr Gary Beale Dr Gillian Patman Julian Leathart Professor Chris Day et al.	The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease	2008
Dr Nicholas Thompson Professor Alastair Burt Professor Chris Day Professor Helen Reeves	Warfarin induced cholestatic jaundice in a patient receiving total parenteral nutrition	2008
Dr Gary Beale Dr Luca Miele Professor Helen Reeves Professor Chris Day	Differential expression of GSTT1 and GSTT2 is associated with more advanced fibrosis in patients with NAFLD	2007
Dr Dipanker Chattopadhyay Professor Helen Reeves	Oncogenes and tumour suppressor genes	2007
Dr Dipanker Chattopadhyay Professor Derek Manas Professor Helen Reeves	The development of targeted therapies for hepatocellular cancer	2007
Dr Luca Miele Dr Gary Beale Julian Leathart Professor Chris Day Professor Helen Reeves et al.	The KLF6 (IVS1-27G > a) polymorphism is associated with non-progressive NAFLD	2007
Professor Chris Day Professor Helen Reeves	The genetic basis of hepatocellular cancer	2006
Professor Helen Reeves	A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and Is associated with increased prostate cancer risk	2005
Professor Helen Reeves	Absence of KLF6 gene mutation in 71 hepatocellular carcinomas: Reply	2005
Professor Helen Reeves	Management of hepatocellular cancer	2005
Professor Helen Reeves	Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread	2005
Dr Barry King Dr Pamela MacDonald Dr Dipanker Chattopadhyay Professor Helen Reeves	The Kruppel-like factor 6 tumour suppressor induces apoptosis in HepG2 cells	2005
Professor Helen Reeves	Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1	2004
Professor Helen Reeves	Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma	2004
Professor Helen Reeves	Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer	2004
Professor Helen Reeves	Novel growth suppressor targets of the KLF6 tumor suppressor gene identified by stringent microarray analysis	2003
Professor Helen Reeves	Activation of hepatic stellate cells: a key issue in liver fibrosis	2002
Professor Helen Reeves	KLF6, a candidate tumor suppressor gene mutated in prostate cancer	2001
Professor Helen Reeves Professor Alastair Burt Professor Chris Day	Integrin receptor expression changes in diseased hepatic stellate cells	2001
Professor Helen Reeves Professor Derek Manas Professor Margaret Bassendine Dr Mark Hudson Emeritus Professor Oliver James et al.	Intravenous bisphosphonate pre liver transplant prevents osteoporotic vertebral collapse	1996
Professor Helen Reeves Professor Alastair Burt Emeritus Professor Oliver James	Lipocyte activation occurs in the absence of hepatitis in alcoholic liver disease and correlates with the severity of steatosis	1994